• 29.March 2018 | Company news |

    EPO joined the AACR Annual Meeting 2018 "Driving Innovative Cancer Science to Patient Care" in Chicago

    between April 14-18.2018

    If you are interested in special approaches or technologies of EPO, please have a look at our posters.

    Poster #1145 / 2 .............. (Download Poster-1145.pdf)
    Humanized immune-PDX mouse models for 10 different tumor entities in translational immuno-oncology research


    Poster #1040 / 13 ............ (Download Poster-1040.pdf)
    Patient derived xenografts of hematologic malignancies for translational research


    Poster #4093 / 21 ............. (Download Poster-4093.pdf)
    Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer

  • 18.October 2017 | Company news |

    EPO presented two posters with new data of selected topics at AACR-NCI-EORTC International Conference in Philadelphia

    Poster #A005
    Drug screening in patient-derived xenografts from acute myeloic leukemia and non-Hodgkin's lymphoma shows correlation with chemotherapy resistance in patients
    The poster will be presented in Poster Session A "Animal Models"
    on Saturday October 28, 2017 12:30 - 4:00 pm
    In Hall E, Pennsylvania Convention Center, Poster Board number 5;
    Abstract #270-Go to online version...

    Poster #A006 - (Pdf download 70 MB)
    Preclinical tumor models in humanized mice for translational immuno-oncology research
    The poster will be presented in Poster Session A "Animal Models"
    on Saturday October 28, 2017 12:30 - 4:00 pm
    In Hall E, Pennsylvania Convention Center, Poster Board number 6;
    Abstract # 272 - Go to online version...

  • 27.July 2017 | Company news |

    AAALAC accreditation for EPO

    EPO received the full accreditation of AAALAC International, a non-profit organization, that promotes responsible laboratory work with highest quality, scientific, and ethical standards through an accreditation program. This major achievement enables us to provide our service following the best up to date rules and conditions in a strictly controlled way.

    For more details see newsletter October 2017.

  • 14.May 2017 | Company news |

    EPO joined the AACR Annual Meeting 2017 in Washington, D.C. and presented there three posters with impressive consideration.

    Poster #1697
    Humanized immune-oncology mouse models
    Go to online version...

    Poster #1843
    Intratumoral heterogeneity of renal cancer is related to differences in drug response and development of therapy resistance.
    Go to online version ...

    Poster #4943
    Orthotopic transplantation of pancreatic cancer PDX models increases murine stroma content, but does not influence therapeutic response to standard of care.
    Go to online version ...

  • 10.February 2017 | Company press release |

    Tracking resistance - new tumor models predict treatment response to anticancer drugs in colon carcinomas

    Together with international colleagues scientists from Berlin found new genetic patterns, which help to predict response in colon cancer.

    go to press release

  • 05.01.2016 | Company news

    January 2016 - EPO collaboration with NexusPharma

    EPO starts strategic collaboration with NexusPharma to foster its market position in the USA.
    see press release ...

  • 05.01.2016 | Company news

    January 2016 - Histopatology service at EPO

    EPO announces a comprehensive histopatology service for experimental in vivo studies. The independent department offers custom-oriented necropsies, tissue processing, preparation of sections, any (immuno) histological staining and evaluation.

Newsletter Login / Logout

Newsletter - March 2018:

EPO@AACR Annual Meeting 2018 in Chicago ... April 14-18.2018
Read more (link)

Newsletter - October 2017:

EPO -October 26-30.2017
AACR-NCI-EORTC International Conference in Philadelphia ...
Read more (link)

EPO received full AAALAC accreditation ...
Read more (link)

Newsletter - September 2017:

EPO offers comprehensive support in the preclinical development of biosimilars ...
Read more (link)

Newsletter - March 2017:

EPO at AACR Annual Meeting 2017 in Washington, D.C.
Read more (link)

Newsletter 4:

EPO has developed a large panel of glioma PDX models. Some of them are growing as orthotopic tumors enabling highly sophisticated studies.
Read more (link)

Newsletter 3:

EPO offers ultrasound imaging for the monitoring of tumor growth.
Read more (link)

Newsletter 2:

EPO has available facilities and device for the use of irradiation in vitro and in vivo.
Read more (link)

Newsletter 1:

Besides expertise for the determination of antitumor efficacy EPO has available special technologies for imaging, radiation, biomarker analysis at protein and molecular level.
Here are some examles (link)

Newsletter - Archiv

2017 © EPO Berlin-Buch GmbH